Molecular mechanisms of insulin resistance in chronic kidney disease

Kidney International

Volumn 88, Issue 6, 2015, Pages 1233-1239

  Thomas, Sandhya S ^a   Zhang, Liping ^a   Mitch, William E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cell signaling; Chronic kidney disease; Inflammation; Insulin resistance

Indexed keywords

ANGIOTENSIN II; CULLIN7 PROTEIN; ELONGIN; FBW8 PROTEIN; FBXO40 PROTEIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; MG53 PROTEIN; MUSCLE PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; PROTEIN KINASE B; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

AGING; AUTOPHOSPHORYLATION; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME MECHANISM; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INSULIN BINDING; INSULIN METABOLISM; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; METABOLIC ACIDOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

EID: 84951568658     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.305     Document Type: Short Survey

References (70)

1. Turcotte LP, Fisher JS. Skeletal muscle insulin resistance: roles of fatty acid metabolism and exercise. Phys Ther 2008; 88: 1279-1296
2. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest 2006; 116: 1813-1822
3. Bailey JL, Price SR, Zheng B et al. Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atroply. J Am Soc Nephrol 2006; 17: 1388-1394
4. Pham H, Utzschneider KM, de Boer IH. Measurement of insulin resistance in chronic kidney disease. Curr Opin Nephrol Hypertens 2011; 20: 640-646
5. Fliser D, Pacini G, Engelleiter R et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-1347
6. DeFronzo RA, Alvestrand A, Smith D et al. Insulin resistance in uremia. J Clin Invest 1981; 67: 563-568
7. Friedman JE, Dohm GL, Elton CW et al. Muscle insulin resistance in uremic humans: glucose transport, glucose transporters, and insulin receptors. Am J Physiol 1991; 261: e87-e94
8. Smith D, DeFronzo RA. Insulin resistance in uremia mediated by postbinding defects. Kidney Int 1982; 22: 54-62
9. May RC, Kelly RA, Mitch WE. Mechanisms for defects in muscle protein metabolism in rats with chronic uremia: the influence of metabolic acidosis. J Clin Invest 1987; 79: 1099-1103
10. Cai D, Yuan M, Frantz DF et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-190
11. Hu Z, Wang H, Lee IH et al. Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J Clin Invest 2009; 119: 7650-7659
12. Zhang L, Du J, Hu Z et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol 2009; 20: 604-612
13. DeFronzo RA. Glucose intolerance and aging: evidence for tissue insensitivity to insulin. Diabetes 1979; 28: 1095-1101
14. Jia T, Huang X, Qureshi AR et al. Validation of insulin sensitivity surrogate indices and prediction of clinical outcomes in individuals with and without impaired renal function. Kidney Int 2014; 86: 383-391
15. DeFronzo RA, Beckles AD. Glucose intolerance following chronic metabolic acidosis in man. Am J Physiol 1979; 236: e328-e334
16. Greenfield MS, Doberne L, Kraemer F et al. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes 1981; 30: 387-392
17. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28: 412-419
18. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005; 25: 391-406
19. Zhang L, Pan J, Dong Y et al. Stat3 activation links a C/EBPdelta to myostatin pathway to stimulate loss of muscle mass. Cell Metab 2013; 18: 368-379
20. Wang XH, Hu Z, Hu JP et al. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology 2006; 147: 4160-4168
21. Ganda A, Magnusson M, Yvan-Charvet L et al. Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis. Circulation 2013; 127: 988-996
22. Shoelson S, Leo J, Goldfine A. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801
23. Pereira BJ, Sundaram S, Snodgrass B et al. Plasma lipopolysaccharide binding protein and bactericidal/permeability increasing factor in CRF and HD patients. J Am Soc Nephrol 1996; 7: 479-487
24. Hotamisligil GS, Arner P, Caro JF et al. Increased adipose tissue expression of tumor necrosis factor-a in human obesity and insulin resistence. J Clin Invest 1996; 95: 2409-2415
25. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91
26. Feinstein R, Kanety H, Papa MZ et al. Tumor necrosis factor-a suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993; 268: 26055-26058
27. Kimmel PL, Phillips TM, Simmens SJ et al. Immunologic function and survival in hemodialysis patients. Kidney Int 1998; 54: 236-244
28. Meuwese CL, Snaedal S, Halbesma N et al. Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-alpha are similarly associated with survival in haemodialysis patients. Nephrol Dial Transplant 2011; 26: 1313-1318
29. Zhang L, Rajan V, Lin E et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 2011; 25: 1653-1663
30. Spoto B, Leonardis D, Parlongo RM et al. Plasma cytokines, glomerular filtration rate and adipose tissue cytokines gene expression in chronic kidney disease (CKD) patients. Nutr Metab Cardiovasc Dis 2012; 22: 981-988
31. Thomas SS, Dong Y, Zhang L et al. Signal regulatory protein-alpha interacts with the insulin receptor contributing to muscle wasting in chronic kidney disease. Kidney Int 2013; 84: 308-316
32. Koppe L, Pillon NJ, Vella RE et al. p-Cresyl sulfate promotes insulin resistance associated with CKD. J Am Soc Nephrol 2013; 24: 88-99
33. Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 2007; 21: 1443-1455
34. Mitch WE, Wilcox CS. Disorders of body fluids, sodium and potassium in chronic renal failure. Am J Med 1982; 72: 536-550
35. Hosoya K, Minakuchi H, Wakino S et al. Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans. Kidney Int 2014; 87: 749-760
36. D'Apolito M, Du X, Zong H et al. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. J Clin Invest 2010; 120: 203-213
37. Graham KA, Reaich D, Channon SM et al. Correction of acidosis in hemodialysis decreases whole-body protein degradation. J Am Soc Nephrol 1997; 8: 632-637
38. Reaich D, Graham KA, Channon SM et al. Insulin mediated changes in protein degradation and glucose utilization following correction of acidosis in humans with CRF. Am J Physiol 1995; 268: e121-e126
39. de Brito-Ashurst I, Varagunam M, Raftery MJ et al. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009; 20: 2075-2084
40. Leal VO, Delgado AG, Leite M et al. The influence of renal function and the diet on acid-base status in chronic kidney disease patients. J Renal Nutr 2009; 19: 178-182
41. Dobre M, Rahman M, Hostetter TH. Current status of bicarbonate in CKD. J Am Soc Nephrol 2014; 26: 515-523
42. Goraya N, Simoni J, Jo C et al. Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy. Kidney Int 2012; 81: 86-93
43. Sacks FM, Svetkey LP, Vollmar WM et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med 2001; 344: 3-10
44. Song Y-H, Li Y, Du J et al. Muscle-specific expression of insulin-like growth factor-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 2005; 115: 451-458
45. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitinproteasome pathway in normal and disease states. J Am Soc Nephrol 2006; 17: 1807-1819
46. Mitch WE, Goldberg AL. Mechanisms of muscle wasting: the role of the ubiquitin-proteasome system. N Engl J Med 1996; 335: 1897-1905
47. Chan JC, Cheung JC, Stehouwer CD et al. The central roles of obesityassociated dyslipidaemia, endothelial activation and cytokines in the Metabolic Syndrome-an analysis by structural equation modelling. Int J Obes Relat Metab Disord 2002; 26: 994-1008
48. Hilton DJ, Richardson RT, Alexander WS et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA 1998; 95: 114-119
49. Emanuelli B, Peraldi P, Filloux C et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 2001; 276: 47944-47949
50. Krebs DL, Hilton DJ. SOCS: physiological suppressors of cytokine signaling. J Cell Sci 2000; 113: 2813-2819
51. Yasukawa H, Sasaki A, Yoshimura A. A negative regulation of cytokine signaling pathways. Annu Rev Immunol 2000; 18: 143-164
52. Mooney RA, Senn J, Cameron S et al. Suppressors of cytokine signaling-1 and-6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 2001; 276: 25889-25893
53. Kawazoe Y, Naka T, Fujimoto M et al. Signal transducer and activator of transcription (STAT)-induced STAT inhibitor 1 (SSI-1)/suppressor of cytokine signaling 1 (SOCS1) inhibits insulin signal transduction pathway through modulating insulin receptor substrate 1 (IRS-1) phosphorylation. J Exp Med 2001; 193: 263-269
54. Okumura F, Matsuzaki M, Nakatsukasa K et al. The role of elongin BC-containing ubiquitin ligases. Front Oncol 2012; 2: 10
55. Rui L, Fisher TL, Thomas J et al. Regulation of insulin/insulin-like growth factor-1 signaling by proteasome-mediated degradation of insulin receptor substrate-1. J Biol Chem 2004; 276: 40362-40367
56. Rui L, Yuan M, Frantz D et al. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002; 277: 42394-42398
57. Bonala S, Lokireddy S, McFarlane C et al. Myostatin induces insulin resistance via casitas B-lineage lymphoma b (Cblb)-mediated degradation of insulin receptor substrate 1 (IRS1) protein in response to high calorie diet intake. J Biol Chem 289: 7654-7670
58. Mohapatra B, Ahmad G, Nadeau S et al. Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases. Biochim Biophys Acta 2013; 1833: 122-139
59. Nakao R, Hirasaka K, Goto J et al. Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading. Mol Cell Biol 2009; 29: 4798-4811
60. Molero JC, Jensen TE, Withers PC et al. c-Cbl-deficient mice have reduced adiposity, higher energy expenditure, and improved peripheral insulin action. J Clin Invest 2004; 114: 1326-1333
61. Molero JC, Turner N, Thien CB et al. Genetic ablation of the c-Cbl ubiquitin ligase domain results in increased energy expenditure and improved insulin action. Diabetes 2006; 55: 3411-3417
62. Molero JC, Waring SG, Cooper A et al. Casitas b-lineage lymphomadeficient mice are protected against high-fat diet-induced obesity and insulin resistance. Diabetes 2006; 55: 708-715
63. Kim BW, Lee CS, Yi JS et al. Lipid raft proteome reveals that oxidative phosphorylation system is associated with the plasma membrane. Expert Rev Proteomics 2010; 7: 849-866
64. Song R, Peng W, Zhang Y et al. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature 2013; 494: 375-379
65. Yokoi N, Fujiwara Y, Wang HY et al. Identification and functional analysis of CBLB mutations in type 1 diabetes. Biochem Biophys Res Commun 2008; 368: 37-42
66. Yi JS, Park JS, Ham YM et al. MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signalling. Nat Commun 2013; 4: 2354
67. Shi J, Luo L, Eash J et al. The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling. Dev Cell 2011; 21: 835-847
68. Xu X, Sarikas A, Dias-Santagata DC et al. The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation. Mol Cell 2008; 30: 403-414
69. Destefano MA, Jacinto E. Regulation of insulin receptor substrate-1 by mTORC2 (mammalian target of rapamycin complex 2). Biochem Soc Trans 2013; 41: 896-901
70. Mashili F, Chibalin AV, Krook A et al. Constitutive STAT3 phosphorylation contributes to skeletal muscle insulin resistance in type 2 diabetes. Diabetes 2013; 62: 457-465.